{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:42:16Z","timestamp":1794278536241,"version":"4.9.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"Importance<\/jats:title>There is a growing interest in understanding whether cardiovascular magnetic resonance (CMR) myocardial tissue characterization helps identify risk of cancer therapy\u2013related cardiac dysfunction (CTRCD).<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe changes in CMR tissue biomarkers during breast cancer therapy and their association with CTRCD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This was a prospective, multicenter, cohort study of women withERBB2<\/jats:italic>(formerlyHER2<\/jats:italic>)\u2013positive breast cancer (stages I-III) who were scheduled to receive anthracycline and trastuzumab therapy with\/without adjuvant radiotherapy and surgery. From November 7, 2013, to January 16, 2019, participants were recruited from 3 University of Toronto\u2013affiliated hospitals. Data were analyzed from July 2021 to June 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Sequential therapy with anthracyclines, trastuzumab, and radiation.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>CMR, high-sensitivity cardiac troponin I (hs-cTnI), and B-type natriuretic peptide (BNP) measurements were performed before anthracycline treatment, after anthracycline and before trastuzumab treatment, and at 3-month intervals during trastuzumab therapy. CMR included left ventricular (LV) volumes, LV ejection fraction (EF), myocardial strain, early gadolinium enhancement imaging to assess hyperemia (inflammation marker), native\/postcontrast T1 mapping (with extracellular volume fraction [ECV]) to assess edema and\/or fibrosis, T2 mapping to assess edema, and late gadolinium enhancement (LGE) to assess replacement fibrosis. CTRCD was defined using the Cardiac Review and Evaluation Committee criteria. Fixed-effects models or generalized estimating equations were used in analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 136 women (mean [SD] age, 51.1\u2009[9.2] years) recruited from 2013 to 2019, 37 (27%) developed CTRCD. Compared with baseline, tissue biomarkers of myocardial hyperemia and edema peaked after anthracycline therapy or 3 months after trastuzumab initiation as demonstrated by an increase in mean (SD) relative myocardial enhancement (baseline, 46.3% [16.8%] to peak, 56.2% [18.6%]), native T1 (1012\u2009[26] milliseconds to 1035\u2009[28] milliseconds), T2 (51.4\u2009[2.2] milliseconds to 52.6\u2009[2.2] milliseconds), and ECV (25.2% [2.4%] to 26.8%\u2009[2.7%]), withP<\/jats:italic>&amp;lt;.001 for the entire follow-up. The observed values were mostly within the normal range, and the changes were small and recovered during follow-up. No new replacement fibrosis developed. Increase in T1, T2, and\/or ECV was associated with increased ventricular volumes and BNP but not hs-cTnI level. None of the CMR tissue biomarkers were associated with changes in LVEF or myocardial strain. Change in ECV was associated with concurrent and subsequent CTRCD, but there was significant overlap between patients with and without CTRCD.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In women withERBB2<\/jats:italic>-positive breast cancer receiving sequential anthracycline and trastuzumab therapy, CMR tissue biomarkers suggest inflammation and edema peaking early during therapy and were associated with ventricular remodeling and BNP elevation. However, the increases in CMR biomarkers were transient, were not associated with LVEF or myocardial strain, and were not useful in identifying traditional CTRCD risk.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.0494","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:02:00Z","timestamp":1681311720000},"page":"524","source":"Crossref","is-referenced-by-count":56,"title":["Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Shalmon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Po Steve","family":"Fan","sequence":"additional","affiliation":[{"name":"Ted Rogers Computational Program, Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, UHN, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Houbois","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yobiga","family":"Thevakumaran","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Somerset","sequence":"additional","affiliation":[{"name":"Ted Rogers Computational Program, Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, UHN, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Malowany","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Urzua-Fresno","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yip","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada"},{"name":"Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada"},{"name":"Techna Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall S.","family":"Sussman","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Yan","sequence":"additional","affiliation":[{"name":"Keenan Research Centre, Li Ka Shing Knowledge Institute, Division of Cardiology, St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Anne","family":"Koch","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Spiller","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Abdel-Qadir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen","family":"Power","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hanneman","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd J.","family":"Wintersperger","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hoi230013r1","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","article-title":"Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography.","volume":"14","author":"Houbois","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"hoi230013r2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.v22.11","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"hoi230013r3","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"hoi230013r4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity.","volume":"73","author":"Gal\u00e1n-Arriola","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230013r5","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1038\/s41598-017-02627-x","article-title":"Early detection and serial monitoring of anthracycline-induced cardiotoxicity using T1-mapping cardiac magnetic resonance imaging: an animal study.","volume":"7","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"hoi230013r6","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.jcmg.2020.01.017","article-title":"T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer.","volume":"13","author":"Martin-Garcia","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"hoi230013r7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ehf2.v5.4","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.","volume":"5","author":"Muehlberg","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"6","key":"hoi230013r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up.","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"hoi230013r9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12968-021-00775-8","article-title":"Multiparametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance.","volume":"23","author":"Giusca","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"hoi230013r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.118.008777","article-title":"Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance.","volume":"12","author":"Lustberg","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"issue":"8","key":"hoi230013r11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004325","article-title":"Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors.","volume":"9","author":"Jordan","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"hoi230013r13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1148\/radiology.211.3.r99jn41698","article-title":"Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats.","volume":"211","author":"Arheden","year":"1999","journal-title":"Radiology"},{"issue":"6","key":"hoi230013r14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1067\/mhj.2001.115436","article-title":"Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study.","volume":"141","author":"Wassmuth","year":"2001","journal-title":"Am Heart J"},{"issue":"4","key":"hoi230013r15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jcmg.2019.10.016","article-title":"Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy\u2014impact of temporal and observer variability.","volume":"13","author":"Altaha","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"hoi230013r16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience.","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"hoi230013r17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"36","key":"hoi230013r18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi230013r21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","article-title":"Multiple imputation by chained equations: what is it and how does it work?","volume":"20","author":"Azur","year":"2011","journal-title":"Int J Methods Psychiatr Res"},{"issue":"4","key":"hoi230013r22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.v30.4","article-title":"Multiple imputation using chained equations: Issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"18","key":"hoi230013r24","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/01.CIR.97.18.1802","article-title":"Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis.","volume":"97","author":"Friedrich","year":"1998","journal-title":"Circulation"},{"issue":"24","key":"hoi230013r25","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi230013r26","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.18632\/oncotarget.v9i5","article-title":"Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.","volume":"9","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"hoi230013r27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jcmg.2016.06.006","article-title":"Progressive 3-month increase in LV myocardial ECV after anthracycline-based chemotherapy.","volume":"10","author":"Mel\u00e9ndez","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"hoi230013r28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-021-08260-7","article-title":"Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.","volume":"32","author":"Tahir","year":"2022","journal-title":"Eur Radiol"},{"key":"hoi230013r29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2018.10.023","article-title":"CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping.","volume":"275","author":"Haslbauer","year":"2019","journal-title":"Int J Cardiol"},{"issue":"4","key":"hoi230013r30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2019.10.020","article-title":"Myocardial extracellular and cardiomyocyte volume expand after doxorubicin treatment similar to adjuvant breast cancer therapy.","volume":"13","author":"Mel\u00e9ndez","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"hoi230013r31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaccao.2020.02.013","article-title":"Fatigue, cardiovascular decline, and events after breast cancer treatment: rationale and design of UPBEAT study.","volume":"2","author":"Jordan","year":"2020","journal-title":"JACC CardioOncol"},{"key":"hoi230013r19","volume-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2012","edition":"2nd ed"},{"key":"hoi230013r20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198524847.001.0001","volume-title":"The Analysis of Longitudinal Data","author":"Diggle","year":"2002"},{"key":"hoi230013r23","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"hoi230013r12","unstructured":"Evaluation of Myocardial Changes During Breast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI (EMBRACE-MRI). ClinicalTrials.gov Identifier: NCT02306538. Updated February 14, 2023. Accessed Month Day, Year. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02306538"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2803933\/jamacardiology_thavendiranathan_2023_oi_230013_1686672882.76249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T15:55:34Z","timestamp":1702223734000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2803933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.0494","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}